Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | PDE9A | O76083 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17116613 | 0.84 | CNR2 (0.51) | TRPV1CNR2HDAC1LRRK2KCNH2 | |
| SCHEMBL1146096 | 0.83 | HDAC1 (0.51) | TRPV1CNR2HDAC1ERBB2ADORA1 | |
| SCHEMBL29768457 | 0.83 | HDAC1 (0.51) | TRPV1CNR2HDAC1ERBB2ADORA1 | |
| SCHEMBL21283226 | 0.82 | CNR2 (0.50) | TRPV1CNR2HDAC1ERBB2ADORA1 | |
| SCHEMBL2471399 | 0.82 | ESR2 (0.53) | TRPV1CNR2HDAC1ADORA1ADORA2A | |
| SCHEMBL24185307 | 0.82 | CNR2 (0.50) | TRPV1CNR2HDAC1ERBB2ADORA1 | |
| SCHEMBL18461458 | 0.82 | HDAC1 (0.51) | TRPV1CNR2HDAC1ADORA1ADORA2A | |
| SCHEMBL5826057 | 0.81 | HDAC1 (0.50) | TRPV1CNR2HDAC1ERBB2ADORA1 | |
| SCHEMBL3288734 | 0.81 | CNR2 (0.49) | TRPV1CNR2HDAC1ADORA1ADORA2A | |
| SCHEMBL10227481 | 0.81 | HPGD (0.58) | TRPV1CNR2HDAC1LRRK2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682941-B2 | Substituted biphenyl analogues as dual inhibitors of aromatase and sulfatase | ESTRYX PHARMA LIMITED (GB) | 2017-06-20 | — | — | US | disclosed |
| US-20170001964-A1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | BEAUFOUR IPSEN TIANJIN PHARMACEUTICAL CO., LTD (CN) | 2017-01-05 | — | — | US | disclosed |
| US-9067928-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-8518970-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-6492397-B1 | SUCH AS 1-PROPYL-4-BUTYL-1,3-DIHYDRO-3-((5-(2-(1H-TETRAZOL-5-YL)PHENYL)-2 -PYRIDINYL)METHYL)-2H-IMIDAZOL-2-ONE; ANGIO-TENSIN II ANTAGONISTS; CIRCULATORY DISORDERS; HYPERTENSION, CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION | 2002-12-10 | — | — | US | disclosed |
| EP-0664802-B1 | N-ARYLHETEROARYLALKYL 1-PHENYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | SEARLE & CO (US) | 2000-03-15 | — | — | EP | disclosed |
| US-5922898-A | Process for preparing biaryl compounds | CATALYTICA PHARMACEUTICALS, INC. (US) | 1999-07-13 | — | — | US | disclosed |
| EP-0579766-B1 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | SEARLE & CO (US) | 1999-06-02 | — | — | EP | disclosed |
| EP-0508393-B1 | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders | SEARLE & CO (US) | 1999-06-02 | — | — | EP | disclosed |
| US-5861420-A | ANGIOTENSIN II ANTAGONISTS | G. D. SEARLE & CO. (US) | 1999-01-19 | — | — | US | disclosed |
| US-5441970-A | Administering angiotensin II antagonists to treat congestive heart failure or hypertension | G. D. SEARLE & CO. (US) | 1995-08-15 | — | — | US | disclosed |
| EP-0664803-A1 | N-ARYLHETEROARYLALKYL 1-CYCLOALKYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1995-08-02 | — | — | EP | disclosed |
| EP-0664802-A1 | N-ARYLHETEROARYLALKYL 1-PHENYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1995-08-02 | — | — | EP | disclosed |
| EP-0619819-A1 | 1-ARYLHETEROARYLALKYL SUBSTITUTED-1H-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS. | SEARLE & CO (US) | 1994-10-19 | — | — | EP | disclosed |
| WO-1994008990-A1 | N-ARYLHETEROARYLALKYL 1-PHENYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1994-04-28 | — | — | WO | disclosed |
| WO-1994008989-A1 | N-ARYLHETEROARYLALKYL 1-CYCLOALKYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1994-04-28 | — | — | WO | disclosed |
| EP-0579766-A1 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1994-01-26 | — | — | EP | disclosed |
| WO-1992018092-A2 | 1-ARYLHETEROARYLALKYL SUBSTITUTED-1H-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-10-29 | — | — | WO | disclosed |
| WO-1992017469-A2 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-10-15 | — | — | WO | disclosed |
| EP-0508393-A1 | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001964-A1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | CYP19A1, SULT2A1, STS | TRPV1 4449/4885CNR2 1874/4885HDAC1 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.